Seres Therapeutics entered into two separate research collaborations with academic groups to support its development of potential microbiome therapeutics for inflammatory bowel disease.
Here are three points:
1. Seres Therapeutics is collaborating with researchers at the Research Institute of St. Joseph's Hamilton in Canada and the Medical University of Graz in Austria.
2. Under the agreements, the academic institutions enhance the company's efforts to develop microbiome-based therapeutics for IBD.
3. Seres' pipeline includes SER-287 and SER-301. SER-287 is the first microbiome therapeutic candidate to reach clinical-stage development in a chronic disease.